[18F]3F-PHPG([18F]3F-PHPG) - 药物靶点：NET_在研适应症：嗜铬细胞瘤，肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名-

靶点

NET

作用方式

调节剂

作用机制

SLC6A2 modulators(去甲肾上腺素转运蛋白调节剂)

治疗领域

肿瘤其他疾病

在研适应症

嗜铬细胞瘤肿瘤

非在研适应症-

原研机构

Rogel Cancer Center: University of Michigan

在研机构

四川大学

Rogel Cancer Center: University of Michigan

非在研机构-

权益机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

关联

3

项与 [18F]3F-PHPG 相关的临床试验

NCT04510311

/ Completed早期临床1期IIT

An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors

The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of [18F]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.

开始日期2020-10-19

申办/合作机构

Rogel Cancer Center: University of Michigan

NCT02669563

/ Completed早期临床1期IIT

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

The main goal of this study is to test two new radioactive drugs, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in human subjects with congestive heart failure.
Evaluations of these imaging agents will include their uptake in heart, lungs and liver, their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies, the better of the two drugs will be chosen for further studies in patients with heart disease. After the better compound is chosen, additional measures of its imaging properties, metabolism and pharmacokinetics will be done in subjects with heart failure.

开始日期2015-12-01

申办/合作机构

University of Michigan

NCT02385877

/ Completed早期临床1期IIT

Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET

The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).

开始日期2015-03-01

申办/合作机构

University of Michigan

100 项与 [18F]3F-PHPG 相关的临床结果

登录后查看更多信息

100 项与 [18F]3F-PHPG 相关的转化医学

登录后查看更多信息

100 项与 [18F]3F-PHPG 相关的专利（医药）

登录后查看更多信息

1

项与 [18F]3F-PHPG 相关的文献（医药）

2025-12-19·JOURNAL OF ORGANIC CHEMISTRY

Automated Synthesis of NET-Targeted PET Tracers [ ¹⁸ F]4F-mHPG and [ ¹⁸ F]3F-pHPG through Photocatalyzed ¹⁸ F-Deoxyfluorination

Article

作者: Wu, Xiaoai ; Xie, Yang ; Yin, Honghai ; Wang, Yueqi ; Hu, Mingxing ; Chen, Wei ; Pan, Lili ; Cao, Yarong

The NET-targeted radiotracers [¹⁸F]4F-mHPG and [¹⁸F]3F-pHPG have demonstrated promising clinical applications; however, the preparation of these tracers remains challenging. Herein, we report an improved synthesis protocol that enables the efficient automated production of two PET tracers via photocatalyzed ¹⁸F-deoxyfluorination. [¹⁸F]4F-mHPG and [¹⁸F]3F-pHPG were prepared in excellent n.d.c. RCYs of 31.3 ± 0.4% and 22.4 ± 1% in only 1 h from readily available precursors, and further validated on the PC12 tumor model for head-to-head comparison.

100 项与 [18F]3F-PHPG 相关的药物交易

登录后查看更多信息